Fredun Pharma's profit jumps 60%, declares 2:1 bonus
FY26 revenue rose 40% to ₹639 crore, but profit grew faster at 60%. The board proposed two new shares for every one held and a final dividend.
— 4 earlier stories on Fredun Pharmaceuticals Ltd. →What's new
- Fredun's FY26 total income rose 40% to ₹639 crore, with EBITDA up 72% to ₹94.8 crore.
- Net profit climbed 60% to ₹33.2 crore on cost discipline and a balanced product mix.
- Board proposed a 2:1 bonus issue and a final dividend of ₹0.70 per share.
Why this matters
Profit growing faster than revenue is a sign the business is scaling efficiently. Pairing the strong results with a bonus issue and dividend signals management intends to return cash to shareholders now.
What we're watching
- Whether the Palghar capacity expansion translates into further profit growth in FY27.
- The impact of the IVR BBB+ credit rating upgrade on borrowing costs.
- Sustainability of demand across its generics, nutraceuticals, and pet pet care segments.
The full read
Fredun Pharmaceuticals delivered a strong year. Revenue rose 40% to ₹639 crore. Profit grew faster: EBITDA jumped 72% to ₹94.8 crore and net profit climbed 60% to ₹33.2 crore. That points to costs being well contained as the business scaled. The company is expanding its Palghar facility and pointed to a credit upgrade to IVR BBB+ as evidence of improved financial standing. The board is sharing the gains, proposing a 2:1 bonus and a final dividend of ₹0.70 per share. The financial trajectory is clear. The next test is whether the new capacity can sustain the pace in FY27.
Questions answered
- Why did Fredun's profit grow faster than its revenue?
- Total income rose 40% but EBITDA jumped 72% and net profit climbed 60%. The company attributed this to cost discipline and a balanced product mix across its business segments.
- What did the board propose for shareholders alongside the results?
- The board recommended a 2:1 bonus issue, giving investors two new shares for every one they own. It also declared a final dividend of ₹0.70 per share.
- What does the credit rating upgrade to IVR BBB+ signify?
- The upgrade reflects improved creditworthiness. This should support the company's borrowing costs as it invests in capacity, including the recent expansion at its Palghar facility.
- Which segments contributed to the growth?
- Management cited a balanced mix across generics, nutraceuticals, and pet care. The press release did not break down the revenue contribution from each segment.
Story so far
All notes on FREDUN →- 25 May 2026 · 5:53 PM IST Fredun Pharma's profit jumps 60%, declares 2:1 bonus
- today Fredun pivots to pet care and physiotherapy, guides 25-30% revenue growth for FY27
- 16d ago Fredun Pharmaceuticals posts 60% profit jump and declares 2:1 bonus
- 16d ago Fredun Pharmaceuticals lifts profit 60% and declares 2:1 bonus
- 16d ago Fredun's profit jumps 60%, board declares 2:1 bonus